Fortunately, elevating ROS levels could inhibit IGF1R bypass signaling and ERK/AKT/nuclear factor κB (NF-κB) signal pathways in the downstream, leading to high efficacy in inhibiting cell proliferation and overcoming bypass signal activation–related GEF resistance in NSCLC treatment (13). The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.